RxDoctor Payments Data

Narine Ourfalian

Family · Boston, MANPI 1982220026

Payments from drug & device makers

$524in general payments, 2019–2025

Across 28 payments — averaging $18.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mylan Specialty L.p.$78
  • Novo Nordisk$70
  • AbbVie$69
  • Biohaven Pharmaceuticals, Inc.$66
  • Biogen$47
  • AstraZeneca$40
  • plus $153 from 7 others

What the payments were for

  • Food & beverage$524100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$524 in reported general payments places this provider in the 70th percentile of 2,320 family providers in Massachusetts.

See all family providers in Massachusetts

Medicare billing

Part B allowed, 2024
$6,540
Medicare patients
35
Services billed
141

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban11$8,246

Paid to pharmacies, not to this prescriber.

Other family in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →